Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Fariba Goodarzian et al.|Clinical Cancer Research|2018Cited by 88
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium studyLars M. Wagner, Peter C. Adamson, Marvin D. Nelson et al.|Pediatric Blood & Cancer|2010Cited by 73